Patented Medicine Prices Review Board 2024-25 Departmental Plan

Patented Medicine Prices Review Board Canada publishes its 2024-25 Departmental Plan, an annual report detailing the department's priorities, programs, expected results, and expenditure plans. The document likely contains textual descriptions of regulatory and financial planning for patented medicines in Canada. It is available under an open government license.

Use Cases

• Analyzing government priorities for patented medicine price regulation based on the described departmental programs.
• Tracking planned expenditures for pharmaceutical regulatory bodies based on the report's financial planning sections.
• Comparing annual strategic objectives for a Canadian regulatory agency based on the documented priorities and expected results.

Strengths

• Available under the OGL-CA-2.0 open government license, facilitating reuse.
• Cross-platform presence on open_canada indicates official publication and accessibility.

Limitations

• No column or structured data information is provided; the dataset appears to be a single HTML document.
• Metadata for size, row count, and specific authorship is absent across all sources.
• The 'last updated' date (2026-04-16) is inconsistent with the 2024-25 plan title, suggesting a potential metadata conflict.

Provenance

Source

Patented Medicine Prices Review Board Canada | Conseil d'examen du prix des médicaments brevetés Canada

Collection Method

Published by the government department as an official report.

Time Range

2024-2025

Freshness

2026-04-16 19:42:45.980111

Geography

Canada